Table 1 Demographic and clinical data of study groups

N

26

33

30

24

Age, years*

62.81 (9.69) [43–79]

73.09 (7.18) [58–86]

63.23 (11.01) [29–82]

60.54 (10.14) [36–77]

< 0.001^‡‡

1.000^‡‡

1.000^‡‡

< 0.001^‡‡

< 0.001^‡‡

0.904^‡‡

Education, years*

13.42 (2.35) [9–16]

9.79 (4.37) [4–18]

9.13 (4.21) [3–18]

10.04 (4.31) [6–18]

< 0.003^‡‡

0.001^‡‡

0.017^‡‡

1.000^‡‡

1.000^‡‡

1.000^‡‡

Sex (female, N, %)

17 (65.38)

15 (45.45)

23 (76.67)

19 (79.17)

0.518^†

0.189^†

0.558^†

0.009^†

0.014^†

1.00^†

Demographic and clinical data

Disease duration, years*

N/A

N/A

13.85 (9.10) [2–28]

11.38 (7.86) [1–28]

0.349^‡

N/A

N/A

DAS 28*

3.09 (1.34) [1.11-6.00]

SHAQ*

1.5 (0.66) [0–2]

RF, (N)

15

Diffuse Systemic sclerosis (N)

12

ACPA (N)

10

Limited Systemic sclerosis (N)

12

Erosions (N)

11

ATA (N)

12

ACA (N)

6

mRSS*

6.35 (4.54) [2–18]

FVC*

88.13 (17.14) [62–119]

DLCO*

59.76 (17.89) [21–97]

ILD (N)

18

GI (N)

17

DU (N)

13

MUSC (N)

3

PAH (N)

1

Antirheumatic treatment

Steroids (N)

17

3

HCQ (N)

6

4

AZA (N)

0

1

MMF (N)

0

8

DMARD (MTX or LEF) (N)

21

0

Biologictherapies (N)

16

8

Vasoreactive therapy (BOS and/orPDE5i) (N)

0

10